196 related articles for article (PubMed ID: 34135020)
1. Unmasking New Promises: Expanding the Antigen Landscape For Antibody-Drug Conjugates.
Oberoi HK; Garralda E
Clin Cancer Res; 2021 Aug; 27(16):4459-4461. PubMed ID: 34135020
[TBL] [Abstract][Full Text] [Related]
2. Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody-Drug Conjugate.
Singh S; Serwer L; DuPage A; Elkins K; Chauhan N; Ravn M; Buchanan F; Wang L; Krimm M; Wong K; Sagert J; Tipton K; Moore SJ; Huang Y; Jang A; Ureno E; Miller A; Patrick S; Duvur S; Liu S; Vasiljeva O; Li Y; Henriques T; Badagnani I; Jeffries S; Schleyer S; Leanna R; Krebber C; Viswanathan S; Desnoyers L; Terrett J; Belvin M; Morgan-Lappe S; Kavanaugh WM; Richardson J
Mol Cancer Ther; 2022 Aug; 21(8):1326-1336. PubMed ID: 35666803
[TBL] [Abstract][Full Text] [Related]
3. Probody therapeutics for targeting antibodies to diseased tissue.
Polu KR; Lowman HB
Expert Opin Biol Ther; 2014 Aug; 14(8):1049-53. PubMed ID: 24845630
[TBL] [Abstract][Full Text] [Related]
4. The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by
Chomet M; Schreurs M; Nguyen M; Howng B; Villanueva R; Krimm M; Vasiljeva O; van Dongen GAMS; Vugts DJ
Theranostics; 2020; 10(13):5815-5828. PubMed ID: 32483421
[TBL] [Abstract][Full Text] [Related]
5. Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index.
Desnoyers LR; Vasiljeva O; Richardson JH; Yang A; Menendez EE; Liang TW; Wong C; Bessette PH; Kamath K; Moore SJ; Sagert JG; Hostetter DR; Han F; Gee J; Flandez J; Markham K; Nguyen M; Krimm M; Wong KR; Liu S; Daugherty PS; West JW; Lowman HB
Sci Transl Med; 2013 Oct; 5(207):207ra144. PubMed ID: 24132639
[TBL] [Abstract][Full Text] [Related]
6. Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies.
Johnson M; El-Khoueiry A; Hafez N; Lakhani N; Mamdani H; Rodon J; Sanborn RE; Garcia-Corbacho J; Boni V; Stroh M; Hannah AL; Wang S; Castro H; Spira A
Clin Cancer Res; 2021 Aug; 27(16):4521-4530. PubMed ID: 34083236
[TBL] [Abstract][Full Text] [Related]
7. Challenges in the development and manufacturing of antibody-drug conjugates.
Ducry L
Methods Mol Biol; 2012; 899():489-97. PubMed ID: 22735971
[TBL] [Abstract][Full Text] [Related]
8. Tumor targeting: activation of prodrugs by enzyme-monoclonal antibody conjugates.
Huennekens FM
Trends Biotechnol; 1994 Jun; 12(6):234-9. PubMed ID: 7765070
[TBL] [Abstract][Full Text] [Related]
9. Safety and Tolerability of Antibody-Drug Conjugates in Cancer.
Wolska-Washer A; Robak T
Drug Saf; 2019 Feb; 42(2):295-314. PubMed ID: 30649747
[TBL] [Abstract][Full Text] [Related]
10. Research progress on novel antibody drug conjugates in cancer therapy.
Li Y; Su J; Tan S; Luo Y; Zhang L
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2024 Feb; 49(2):296-304. PubMed ID: 38755726
[TBL] [Abstract][Full Text] [Related]
11. Antibody-drug conjugates: using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells.
Goldmacher VS; Kovtun YV
Ther Deliv; 2011 Mar; 2(3):397-416. PubMed ID: 22834009
[TBL] [Abstract][Full Text] [Related]
12. Antibody drug conjugates: Progress, pitfalls, and promises.
Mukherjee A; Waters AK; Babic I; Nurmemmedov E; Glassy MC; Kesari S; Yenugonda VM
Hum Antibodies; 2019; 27(1):53-62. PubMed ID: 30223393
[TBL] [Abstract][Full Text] [Related]
13. Bioanalysis special focus issue on antibody-drug conjugates.
Kaur S
Bioanalysis; 2013 May; 5(9):981-3. PubMed ID: 23641688
[No Abstract] [Full Text] [Related]
14. [An overview of antibody-based cancer therapy].
Miao QF; Shao RG; Zhen YS
Yao Xue Xue Bao; 2012 Oct; 47(10):1261-8. PubMed ID: 23289136
[TBL] [Abstract][Full Text] [Related]
15. Antibody conjugate therapeutics: challenges and potential.
Teicher BA; Chari RV
Clin Cancer Res; 2011 Oct; 17(20):6389-97. PubMed ID: 22003066
[TBL] [Abstract][Full Text] [Related]
16. Cancer-targeting antibody-drug conjugates drive dealmaking frenzy.
Senior M
Nat Biotechnol; 2024 Mar; 42(3):362-366. PubMed ID: 38409588
[No Abstract] [Full Text] [Related]
17. Management of Multiple Myeloma with Second-Generation Antibody-Drug Conjugates.
Robak P; Robak T
BioDrugs; 2016 Apr; 30(2):87-93. PubMed ID: 26927803
[TBL] [Abstract][Full Text] [Related]
18. Picking the optimal target for antibody-drug conjugates.
Mathur R; Weiner GJ
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714470
[TBL] [Abstract][Full Text] [Related]
19. Antibody-targeted drugs and drug resistance--challenges and solutions.
Shefet-Carasso L; Benhar I
Drug Resist Updat; 2015 Jan; 18():36-46. PubMed ID: 25476546
[TBL] [Abstract][Full Text] [Related]
20. Ongoing development of monoclonal antibodies and antibody drug-conjugates in lymphoma.
Boyle EM; Morschhauser F
Curr Oncol Rep; 2011 Oct; 13(5):386-97. PubMed ID: 21845421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
